deltatrials
Completed PHASE2/PHASE3 INTERVENTIONAL 4-arm NCT04649151

A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19 (TeenCove)

A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 Years of Age

Sponsor: Biomedical Advanced Research and Development Authority

Conditions SARS-CoV-2
Updated 20 times since 2021 Last updated: Aug 25, 2025 Started: Dec 9, 2020 Primary completion: Jun 14, 2024 Completion: Jun 14, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates SARS-CoV-2 and is currently completed. Biomedical Advanced Research and Development Authority leads this study, which shows 20 recorded versions since 2020 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Feb 2022 · 5 months · monthly snapshot~Feb 2022 – ~May 2022 · 3 months · monthly snapshot~May 2022 – ~Nov 2022 · 6 months · monthly snapshot~Nov 2022 – ~Feb 2023 · 3 months · monthly snapshot~Feb 2023 – ~Apr 2023 · 59 days · monthly snapshot~Apr 2023 – ~Jun 2023 · 2 months · monthly snapshot~Jun 2023 – ~Sep 2023 · 3 months · monthly snapshot~Sep 2023 – ~Dec 2023 · 3 months · monthly snapshot~Dec 2023 – ~Feb 2024 · 2 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Sep 2025 · 10 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – present · 9 months · monthly snapshot

Change History

20 versions recorded
  1. Oct 2025 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Sep 2025 — Oct 2025 [monthly]

    Completed PHASE2/PHASE3

  3. Nov 2024 — Sep 2025 [monthly]

    Completed PHASE2/PHASE3

  4. Sep 2024 — Nov 2024 [monthly]

    Completed PHASE2/PHASE3

  5. Aug 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

Show 15 earlier versions
  1. Jul 2024 — Aug 2024 [monthly]

    Completed PHASE2/PHASE3

    Status: Active Not RecruitingCompleted · Phase: PHASE2_PHASE3PHASE2/PHASE3

  2. Feb 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  3. Dec 2023 — Feb 2024 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  4. Sep 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE2_PHASE3

    Status: RecruitingActive Not Recruiting

  5. Jun 2023 — Sep 2023 [monthly]

    Recruiting PHASE2_PHASE3

  6. Apr 2023 — Jun 2023 [monthly]

    Recruiting PHASE2_PHASE3

  7. Feb 2023 — Apr 2023 [monthly]

    Recruiting PHASE2_PHASE3

    Status: Active Not RecruitingRecruiting

  8. Nov 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE2_PHASE3

    Status: RecruitingActive Not Recruiting

  9. May 2022 — Nov 2022 [monthly]

    Recruiting PHASE2_PHASE3

    Status: Active Not RecruitingRecruiting

  10. Feb 2022 — May 2022 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  11. Sep 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  12. Apr 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2_PHASE3

    Status: RecruitingActive Not Recruiting

  13. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE2_PHASE3

  14. Feb 2021 — Mar 2021 [monthly]

    Recruiting PHASE2_PHASE3

    Status: Not Yet RecruitingRecruiting

  15. Jan 2021 — Feb 2021 [monthly]

    Not Yet Recruiting PHASE2_PHASE3

    First recorded

Dec 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Biomedical Advanced Research and Development Authority
  • ModernaTX, Inc.
Data source: ModernaTX, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .